🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with data suggesting in excess of 82 million infections each year. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was authorized by the US Food and Drug Administration in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the development of resistance.

Another new antibiotic, created by the drugmaker GSK, gained clearance in concurrent days. This medication, which is employed against UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment stemmed from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the management of highly resistant gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Global Access

According to data detailed in a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which involves a dual-drug approach. The trial included nearly 1,000 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the rights to license and sell the drug in a wide range of regions with limited resources.

Doctors directly involved have voiced positive views. The availability of a easy-to-administer therapy like this is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.